For people living with knee osteoarthritis, today's treatments mostly manage pain until the joint is worn out enough to replace. A new cell therapy presented at the American College of Rheumatology's ACR Convergence 2026 in Orlando suggests that may not always have to be the endgame. In a 113-patient phase 2a trial, a single knee injection called OSCA roughly halved pain over six months and, on MRI, showed early signs of cartilage regrowth (MedPage Today). MedPage Today's headline put it boldly...